SkinBioTherapeutics Plc Profit Margin

SkinBioTherapeutics Plc (SBTX.L) currently reports a profit margin of -38.34% as of December 2025. That compares with -2020.22% in the prior-year period — up 98.1% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore SkinBioTherapeutics Plc's profit margin history and peer comparisons.

SkinBioTherapeutics Plc's profit margin increased from -2020.22% to -38.34% — a 98.1% year-over-year increase (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

SkinBioTherapeutics Plc's profit margin of -38.34% is lower than the Healthcare sector average of 10.58%. That is roughly 462.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but SkinBioTherapeutics Plc's current -38.34% should be judged against Healthcare norms (sector average: 10.58%) and against SBTX.L's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -38.34%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for SkinBioTherapeutics Plc, and consider following SBTX.L for alerts when major investors trade the stock.